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Abstract
Covid-19 is a pandemic and the whole world is facing the loss in terms of mor-
bidity and mortality of the human resources. Therefore, there is an urgent need for 
various therapeutic agents or drugs to treat the covid-19 patients. Although, vac-
cination process is under way, it is not possible to provide the vaccination to whole 
world in a short period. Therefore, it is an essential strategy to work on the various 
therapeutic aspects of covid-19 treatment. The present book chapter will discuss 
and review the various aspects of the treatment strategies of the covid-19. Further, 
we will provide an overview of the virus and host based potential therapeutic 
targets along with existing therapeutics which are effective against SARS-CoV-2 
virus. Also, the novel vaccines are being developed against covid-19 deadly virus 
will be discussed.
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1. Introduction
The new covid-19 pandemic was reported in Wuhan, China in December, 2019 
[1]. This disease is caused by corona virus also known as SARS-CoV-2 and charac-
terized by severe acute respiratory distress syndrome [2]. As per the recent report of 
WHO on 20 December, 2020, there have been over 75 million cases and 1.6 million 
deaths reported worldwide since the start of the pandemic [3]. In 2002, SARS-CoV 
(Severe Acute Respiratory Syndrome Coronavirus) outbreak was reported in China 
then spread worldwide, whereas, MERS-CoV (Middle East Respiratory Syndrome 
Coronavirus) emerged in Saudi Arabia in 2012 with 37% mortality rate. Similar to 
SARS and MERS, newly identified severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) belongs to beta-coronaviridae family and showed close resemblance 
with them [4]. These three zoonotic viruses have pandemic potential and able to 
produce severe respiratory infection in humans [5].
The SARS-CoV-2 infection is transmitted through respiratory secretions either 
in droplet or aerosol form from one person to another [6]. Apart from respiratory 
secretions, urine, stool and close proximity with patients may be the sources for 
dissemination of SARS-CoV-2 [7, 8]. Based on phylogenetic studies, the genomic 
sequence of SARS-CoV-2 virus is 96% similar to bat corona viruses so these bats 
may be potential reservoir host for human corona virus [9]. However, there are 
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no clear evidences which have suggested virus transmission directly from bats to 
human population [10]. Further, some studies suggested that pangolins can be 
considered as intermediate hosts between bats and human [11, 12]. Severe infec-
tious covid-19 cases have rapidly progressed to dyspnoea, shock and acute respira-
tory distress [13]. In addition, the other organ dysfunctions have also been reported 
from patients including severe cardiac injury, acute renal, gastrointestinal, liver 
injury, neurological defect along with coagulation impairment and death [13].
It is important to understand the virus biology, and replication cycle to identify 
effective therapies against SARS-CoV-2, because most of therapies are directly 
targeting the stages in the virus life cycle. Highly pathogenic SARS-CoV-2 are envel-
oped, single-stranded positive sense RNA betacoronavirus with size ranging from 
80–120 nm, and their genomes encode non-structural proteins (nsps), structural 
proteins, and several accessory proteins [14]. Genome of RNA virus contains ten 
open reading frames (ORF1–10) and has total 29,903 nucleotides [15]. Among the 
ten ORFs ORF2–10 generates four structural proteins S (spike), N (nucleocapsid),  
E (Envelop protein), M (Membrane protein) along with auxillary proteins. 
However, large replicase polyproteins (PP1a/b) encoded by ORF1ab further gets 
cleaved by proteolytic enzymes into non structural proteins (nsp1–16) [15].
The SARS-CoV-2 virus entry in host cell is mediated with attachment of the spike 
(S) glycoprotein with the host angiotensin-converting enzyme 2 (ACE2) receptor 
thereby infection process starts [16]. Further, virus S protein cleaved by the cathepsin 
L proteases which get activated in a pH- dependant manner allows the release of 
viral genome into host cell cytoplasm [17]. In addition, other host cell proteases like 
TMPRSS2 (Transmembrane Protease Serine Type-2) and TMPRSS11D (Airway 
trypsin like protease) participate in the cleavage of spike protein into its constituents 
(S1 and S2) which further lead to entry of virus genome into host cell through non 
endocytic pathway [18]. S1 subunit of spike protein possesses receptor binding 
domain (RBD) which binds with host receptors and S2 subunit favors fusion of viral 
membrane with host cell [19]. Once the virus genome released inside the host cell, 
then host ribosomes are involved in the process of translation of virus genome con-
taining ORF1ab into replicase polyproteins PP1ab [20]. These PP1ab further cleaved 
by important viral proteases include 3CLpro (3 chymotrypsin like proteases) and 
PLpro (papain like proteases) to generate nsp2–16 [20]. These nsp2–16 are partici-
pated in virus replication and transcription complex, while virus structural proteins 
are translated from another ORF2–10 containing viral genome and contribute to 
outer structure of virus [21]. At last, the newly born virions are delivered outside 
the infected cell by exocytosis after completion of their structural assembling in the 
endoplasmic reticulum golgi bodies complex [22].
The WHO (world health organization) has declared covid-19 a public health 
emergency due to its high spreading potential across the world. Although, vaccine 
development trial has almost finished and vaccination drive is going to be started. 
However, till now there are no effective therapies or specific drug candidates against 
this communicable disease. Thus, it is required to understand detail biology of virus 
(SARS-CoV-2) to further elucidate novel drug therapeutics.
2. Therapeutic agents to tackle the covid-19 infection
2.1 ACE-2 modulators
Like SARS-CoV, it is confirmed that SARS-CoV-2 virus also interacts with ACE-2 
human enzyme for entry and replication into the host cell. SARS-CoV-2 spike pro-
tein has high binding affinity with ACE-2 enzyme present in respiratory epithelial 
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cell of host [23]. Hence, the therapeutics which inhibit spike protein-ACE-2 interac-
tion would be considered effective therapy against SARS-CoV-2. ACE-2 enzyme is 
a zinc metalloproteinase which contains two domains in its structure which include 
amino terminal domain and carboxy terminal domain [5]. ACE-2 enzymes are 
exhibits in type-I and type-II alveolar cells of respiratory tract, liver, kidney, testes, 
heart and intestine [24]. Wu et al. [25] have found that ACE-2 enzymes are highly 
expressed in alveolar epithelial type-II cells in an around 83% which indicate these 
cell can be served as reservoir for virus. ACE-2 enzyme is a key regulator protein of 
RAS (Renin-Angiotensin System) system which contributes to vascular homeostasis 
[26]. In RAS system, angiotensinogen glycoprotein is cleaved by renin enzyme 
present in kidney to angiotensin-I, which has converted into angiotensin-II (Ang-II) 
by ACE-1. Further, Ang-II binds to angiotensin receptor (ATR1) and produces 
vasoconstriction, cell proliferation, inflammation, thrombosis and vascular con-
striction [27]. For the counterbalance of AngII- ATR1 axis effect, AngII is cleaved by 
ACE-2 enzymes into Ang1–7 peptides [28]. These angiotensin peptides further act 
on MASR (mitochondrial assembly receptor) and exhibits protective effects such 
as anti-inflammatory, anti-apoptotic and vasodilatation. Rothlin and co-worker 
[29] have reported the protective effects of ACE inhibitors and angiotensin recep-
tor blockers (ARBs). They have found that patients with Covid-19 infection are 
taking ACE inhibitors and angiotensin receptor blockers exhibited lower mortality 
as compared with non-user patients. Previous study revealed that SARS-CoV virus 
down-regulates the ACE-2 enzymes present in host cell surface and increased ACE 
enzyme activity which lead to severe lung injury [30]. Increased ACE enzyme activ-
ity has been observed in SARS-CoV-2 patients. Hence, it has been proposed that 
delivery of soluble ACE-2 recombinant protein compete with host ACE-2 enzymes 
for the SARS-CoV-2 spike protein and ultimately neutralize the virus load and 
further, protect the patients from lung injury. For this purpose, recombinant human 
ACE-2 such as APN01 and GK2586881 have been analyzed and found effective in 
patient suffered from acute severe respiratory syndrome (Figure 1) [31].
2.2 TMPRSS2 inhibitors
Transmembrane serine protease-2 (TMPRSS-2) is present in host epithelium 
cells of various tissues [32]. It is involved in the pathogenesis of SARS-CoV-2 
through cleavage of spike protein and facilitates virus entry into host cell [33]. 
Matsuyama et al. [34] demonstrated that over-expressed protein TMPRSS-2 
containing vero E6 cell lines are susceptible for SARS-CoV virus infection and 
used as pharmacological tool for SARS-CoV-2 research. Thus any drug candidate 
which inhibits TMPRSS-2 protease may be effective in SARS-CoV-2 infection. In 
this regard, in vitro study conducted against SARS-CoV-2 to check the efficacy of 
compound camostat mesylate blocked the spike mediated virus entry in caco-2 
cells [35]. In addition, some repurposing studies have been conducted to evaluate 
the efficacy of other proteases inhibitors such as nafamostat, 4-(2 aminomethyl) 
benzenesulfonyl fluoride and mucolytic drug bromhexine which can offer new 
therapeutic option for this pandemic (Figure 1) [36, 37].
2.3 JAK–STAT inhibitors
In covid-19 infection, patients suffer from severe acute respiratory syndrome 
in which huge amounts of various cytokines are released from immune cells lead-
ing to multiorgan failure and death [38]. Moreover, JAK–STAT signaling pathway 
is involved in SARS-CoV-2 virus entry into host cell which has linked with AAK1 
(Adaptor-associated protein kinase-1) related clathrin mediated endocytosis [39]. 
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Activation of JAK–STAT pathway through Ang-II/AT1R may generate cytokines 
storm including IL-1, IL-2, IL-6, IL-7, IL-10 and TNF-α [39]. Thus, it may be sug-
gested that JAK–STAT inhibitors could be potential therapeutics for the covid-19 
infection. Further, Junior and co-workers [40] have shown that baricitinib, a 
JAK–STAT inhibitor, has potential to prevent generation of cytokines through 
inhibition of JAK–STAT signaling and also block the entry of SARS-CoV-2 via 
inhibiting AAK1 related clathrin mediated  endocytosis (Figure 1).
2.4 Cathepsin L inhibitors
Cathepsin L is a cysteine protease reside in endosomes and works in acidic pH [41]. 
It cleaves S1 virus spike glycoprotein and facilitates three actions including virus entry 
into host cell, virus-host cell endosomal membrane fusion and RNA release. Serine 
protease (TMPRSS-2) acts on the surface of host cell membrane in neutral pH [42], 
whereas, cathepsin L mediates its action at host cell membrane as well as inside the 
endosomes in acidic pH [43]. Therefore, Liu and coworkers, [17] have proposed that 
the combined use of serine protease and cathepsin-L inhibitors could be effective ther-
apeutics to prevent virus entry and their genome release inside the host cell thereby 
inhibit the virus replication. In addition, they have also mentioned some cathepsin-L 
Figure 1. 
Diagram showing the therapeutics approach to treat the infection of covid-19 patients.
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inhibitors compounds which are found effective against coronavirus infection such as 
dec-RVKR-CMK, K11777, small molecule 5705213, MDL28170, SSAA09E1, EST, and 
oxocarbazate. Based on the proposed mechanism, it is reported that the combined 
use of TMPRSS-2 inhibitors including camostat and nafamostat mesylate along with 
cathepsin-L inhibitor E64d have shown inhibitory potential against SARS-CoV and 
SARS-CoV-2 infection in human epithelial cells (Figure 1) [44].
2.5 Furin inhibitors
Furin, is a human protease enzyme, present in multiple tissues and highly 
expressed in lungs [45]. It has been reported that SARS-CoV-2 virus contains furin 
like cleavage site (FCS) in its spike protein which has made covid-19 virus more 
pathogenic in nature as compared to other ancestors virus of coronaviridae family 
[46]. SARS-CoV-2 virus utilizes host furin protease for the cleavage of spike protein 
and gain entry into the host cell. Moreover, mortalities from SARS-CoV-2 infection 
have been reported in those patients compromised with cardiac disease, diabetes, 
obesity and hypertension and likely to be associated with higher circulating furin 
level [47]. Hence, scientists have drawn attention towards furin inhibitors to 
provide new therapeutic intervention against covid-19 infection (Figure 1).
2.6 Inhibitors of virus structural proteins and enzymes
Structural proteins and virus encoded enzymes of SARS-CoV-2 may be con-
sidered as important drug targets because these are responsible for virus survival 
and propagation. Researchers and pharmaceuticals companies have focused to 
develop short interfering RNA (siRNA) based therapeutics to target virus struc-
tural proteins and enzymes such as 3CL pro, PLpro and RNA dependant RNA 
polymerases to combat covid-19 infection [48]. Some previous studies revealed 
that siRNA therapeutics have already been designed against SARS-CoV and MERS 
viruses and found effective in outbreaks [49]. In addition, heptad repeat 1 region 
(HR1) present in the S protein involved in fusion and entry of virus could also be 
a good target for the development of fusion inhibitors against covid-19 [50]. Xia 
and co-workers, [51] have developed EK1C4 fusion inhibitors which target SARS-
CoV-2 spike protein and found effective in HCoV-OC43 challenged mice. Recently 
in clinical trials, many chemical peptides, existing drugs and new drug candidates 
have been recognized through virtual and high throughput screening techniques 
against SARS-CoV-2 coded enzyme proteases [52]. Based on computational strat-
egy, 6LU7PDB compound has been identified which acts as non-covalent inhibitor 
of 3CL pro enzyme in SARS-CoV-2 infection [53]. Some 3CL pro enzyme inhibitors 
antiviral drugs such as lopinavir and ritonavir have been found effective against 
SARS-CoV-2 virus infection [54]. In addition, some therapeutics are also identi-
fied which showed high binding affinity with SARS-CoV PLpro enzyme such as 
ribavirin, valganciclovir, beta-thymidine and some natural products like platycodin 
D, baicalin and catechin [55]. Moreover, RNA dependant RNA polymerase (RdRp) 
inhibitor antiviral drug remdesivir was approved by FDA for emergency treatment 
for covid-19 patients [56]. However, still its role is controversial for the treatment of 
covid-19 patients (Figure 1).
2.7 Inhibitors of cytokines
During covid-19 infection, higher amounts of cytokines have secreted from 
inflammatory cells and serve as potential therapeutic targets for drug development. 
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The major cytokines, IL-6, IL-1, TNF and interferons are generated during cytokine 
storm which cause the increased vascular permeability, vascular leakage along with 
dissemination of virus which may lead to fatal pneumonia and acute respiratory 
distress syndrome [57, 58]. However, many neutralizing strategy against these 
inflammatory mediators are being used to cope with this cytokine storm in covid-19 
pandemic. Chi and co-workers, [59] reported the use of antibodies against IL-6 
receptor (tocilizumab and sarilumab) for the treatment of covid-19 infection. 
Anti-TNF drug etanercept has shown favorable effect in covid-19 patients [60]. 
Moreover, another targeting approach against cytokine IL-1 is important because 
it is the major cytokine present in higher amount in alveolar lavage of covid-19 
patients and secreted from inflammatory macrophages and monocytes [61]. Cavalli 
& coworkers, [62] have reported the use of anakirna in high dose and found safe in 
72% patients suffered from covid-19 and ARDS with non-invasive ventilation out-
side the ICU. Furthermore, interferons (IFNs) have immunostimulant and antiviral 
effects and their use as a treatment along with some antiviral drugs have been found 
effective against MERS, SARS and IBV viruses (Figure 1) [63].
2.8 Antiviral drugs
As per the previous information related with SARS & MERS outbreak, many 
existing anti-viral drugs are being repurposed against SARS-CoV-2 virus in covid-
19 pandemic. Remdesivir is a prodrug that converts into active metabolite and 
inhibits RNA dependant RNA polymerases (RdRp) thereby preventing the viral 
RNA synthesis [64]. It is prescribed against ebola virus infection and reported 
to have in vitro antiviral activity towards SARS and MERS coronaviruses [56]. 
Recently, it was reported that remdesivir prevents SARS-CoV-2 infection in human 
liver cancer cells [65]. Based on one clinical trial, remdesivir has been found 
clinically effective in 36 out of 53 patients suffered from covid-19 infection and 
receiving oxygen support [66]. In addition, many clinical trials are being carried 
out to check efficacy of remdesivir in covid-19 patients in various countries. Hung 
& co-workers, [67] have conducted clinical trial by using the combination of triple 
antiviral drug include lopinavir, ritonavir and ribavirin along with interferon 
which were found more promising compared to antiviral drug used alone in patient 
suffered from covid-19 infection. Another antiviral drug, favipiravir inhibits viral 
RNA polymerase enzyme and reported to have antiviral activity against many 
RNA viruses such as influenza, bunya and filoviruses [68]. However, to check the 
clinical efficacy of favipiravir in covid-19 patients various clinical trials have been 
performed in China and found favorable results (Figure 1) [13].
2.9 Corticosteroids
Corticosteroids are extensively used for SARS-CoV, MERS-CoV, H1N1 influenza, 
and ARDS that have similar pathological features with covid-19. But, their role in 
reducing mortality and improving these conditions remain controversial [69]. It 
was reported that corticosteroids did not improve the outcome during the SARS 
and MERS outbreaks, but delayed viral clearance and increased rates of secondary 
infections [70]. A systemic review and meta-analysis are conducted in covid-19 
patients by van-Paassen et al. [71], their findings based on observational and 
clinical studies suggested the beneficial effects of corticosteroids on mortality rate 
and reduced ventilation support. However, delayed viral clearance and increased 
secondary infection have also been observed. Similarly, the study has been con-
ducted in China in 201 patients confirmed with covid-19 pneumonia. In 62 patients 
who received methylprednisolone likely had decrease risk of death [72]. As per 
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another report of Mishra & Mulani, [73] corticosteroids are not recommended in 
the late course of acute respiratory distress syndrome (ARDS) condition because 
their persistent use more than 2 weeks has increased risk of death in ARDS patients. 
It seems that corticosteroid treatment work like double edged sword in covid-19 
fight, therefore duration of corticosteroid therapy needs to be clarified in clinical 
trials (Figure 1).
2.10 Convalescent plasma therapy
Convalescent plasma is obtained from donors who have recovered from covid-
19 infection, possess antibodies against SARS-CoV-2 that may neutralize the virus 
and modify the immune response [74]. Convalescent plasma therapy offers short 
term protection strategy and generates immediate immune response in suscep-
tible patients. This approach has already been used in earlier outbreak of corona 
viruses such as SARS and MERS [75]. In this corona pandemic, many clinical 
trials have also been conducted against SARS-CoV-2. Recently the clinical study 
conducted by Duan et al. [76] revealed that the convalescent plasma therapy was 
well tolerated and positively improved the clinical outcomes in severe covid-19 
patients. Salazar et al. [77] reported the use of convalescent plasma therapy in 25 
patients who had severe covid-19 disease and evaluated safety along with clinical 
outcomes at 14 day after the transfusion. They found clinical improvement in nine 
patients within seven days and other were discharged at day 14. Hence, convales-
cent plasma therapy has potential to treat covid-19 cases but some adverse events 
have also been reported such as allergic reaction, dyspnoea and acute lung injury 
[78] (Figure 1).
2.11 Ivermectin
Ivermectin is an broad spectrum antiparasitic drug and its antiviral activity 
has also been reported against number of viruses both in vitro and in vivo [79]. 
Recently, in vitro study revealed that ivermectin can inhibit SARS-CoV-2 replication 
by reducing viral RNA up to 5000 fold at 48 h. in culture cells [80]. However, the 
mechanism of action of ivermectin is not clearly known. Choudhry and Sharma, 
[81] have mentioned that ivermectin may act by creating acidic environment and 
blocking the importin IMP2/β1 mediated viral intranuclear import (Figure 1).
2.12 Hydroxychloroquine
Hydroxychloroquine has been prescribed since decades in the prevention and 
treatment of malaria as well as rheumatoid arthritis and systemic lupus erythema-
tosus (SLE) like chronic inflammatory condition [82]. In SARS-CoV-2 pandemic, it 
was suggested that hydroxychloroquine may have potential to treat covid-19 affected 
patients [83]. Food and Drug Administration (FDA) has granted permission for 
emergency use of hydroxychloquine in the treatment of covid-19 patients during 
initial stage of pandemic [84]. Recently, many in vitro studies have been conducted 
and found that hydroxychloroquine possess inhibitory activity against SARS-CoV-2 
[85, 86]. Further, several studies have been published regarding the use of hydroxy-
chloroquine in covid-19 but results are conflicting. One population based cohort 
study conducted by Rentsch and coworkers, [87] stated that there was no difference 
observed in mortality of covid-19 patients who had already received hydroxychlo-
roquine for the treatment of rheumatoid arthritis or systemic lupus erythematosus. 
Similarly, in an observational study in covid-19 hospitalized patients, hydroxychlo-
roquine did not show any benefit over mortality reduction (Figure 1) [88].
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2.13 Vaccines
Various vaccine developments are being carried out across the world due to 
urgent need to overcome this covid-19 pandemic. Now in covid-19 emergency, 
vaccines could only be considered as potent therapeutics against SARS-CoV-2 
deadly virus which normalize social life and working environment as it was earlier 
before pandemic. For the effective vaccines development against SARS-CoV-2 
virus, various components are being used which include inactive or live-attenuated 
viruses, virus-like particles, viral vectors, protein-based, DNA-based, and mRNA-
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developed and undergone for vaccination shot which have completed their clinical 
evaluation phase successfully [90]. However, several new vaccines are still under 
clinical developmental phase (Figure 1). Some important vaccines which are being 
developed against SARS-CoV-2 virus are mention below in Table 1.
3. Conclusion
Covid-19 is a devastating situation to the whole world and this infection is the 
reason for the morbidity and mortality of millions of people around the globe. It 
has shown impact on the health, economy and social aspect of the general popula-
tion. Various therapeutic agents like ACE-2, TMPRSS2, JAK–STAT, cathepsin L, 
furin inhibitors, antiviral drugs, corticosteroids and plasma therapy have been 
tried for the treatment of covid-19 infected patients; however, conflicting results 
are obtained during the various clinical trials in the use of some therapeutic agents. 
Further, various vaccination programmes through various vaccine candidates are 
under progress; nevertheless, it will take time to complete dosing the millions of 
people. Therefore, various therapeutic agents are in need and require research to 
tackle this SARS-CoV-2 infection.
Conflict of interest
The authors declare no conflict of interest.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
10
Biotechnology to Combat COVID-19
References
[1] Zhu H, Wei L, Niu P. The novel 
coronavirus outbreak in Wuhan, China. 
Global health research and policy. 2020 
Dec; 5(1):1-3.
[2] Mohanty SK, Satapathy A, Naidu MM, 
Mukhopadhyay S, Sharma S, Barton LM, 
Stroberg E, Duval EJ, Pradhan D, 
Tzankov A, Parwani AV. Severe acute 
respiratory syndrome coronavirus-2 
(SARS-CoV-2) and coronavirus disease 
19 (COVID-19)–anatomic pathology 
perspective on current knowledge. 
Diagnostic Pathology. 2020; 15(1):1-17.
[3] World Health Organization.  
COVID-19 weekly epidemiological 
update, 22 December 2020.
[4] Pal M, Berhanu G, Desalegn C, 
Kandi V. Severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2): 
an update. Cureus. 2020; 12(3).
[5] Gil C, Ginex T, Maestro I, Nozal V, 
Barrado-Gil L, Cuesta-Geijo MÁ, 
Urquiza J, Ramírez D, Alonso C, 
Campillo NE, Martinez A. COVID-19: 
drug targets and potential treatments. 
Journal of Medicinal Chemistry. 2020; 
63(21):12359-86.
[6] Lu CW, Liu XF, Jia ZF. 2019-nCoV 
transmission through the ocular surface 
must not be ignored. Lancet (London, 
England). 2020; 395(10224):e39.
[7] Saawarn B, Hait S. Occurrence, 
fate and removal of SARS-CoV-2 
in wastewater: Current knowledge 
and future perspectives. Journal of 
Environmental Chemical Engineering. 
2020; 104870.
[8] Dhiman R, Rakheja V, Saxena R. 
An Ophthalmologist's Insight Into The 
Viral Pandemics. Journal of Optometry. 
2021 Jan 6.
[9] Flores-Alanis A, Sandner-
Miranda L, Delgado G, Cravioto A, 
Morales-Espinosa R. The receptor 
binding domain of SARS-CoV-2 spike 
protein is the result of an ancestral 
recombination between the bat-CoV 
RaTG13 and the pangolin-CoV MP789. 
BMC research notes. 2020; 13(1):1-6.
[10] Kumar R, Lee MH, Mickael C, 
Kassa B, Pasha Q , Tuder R, Graham B. 
Pathophysiology and potential future 
therapeutic targets using preclinical 
models of COVID-19. ERJ Open 
Research. 2020; 6(4).
[11] Zhao J, Cui W, Tian BP. The 
potential intermediate hosts for SARS-
CoV-2. Frontiers in Microbiology. 
2020; 11.
[12] Zhang T, Wu Q , Zhang Z.  
Probable pangolin origin of SARS-
CoV-2 associated with the COVID-19 
outbreak. Current Biology. 2020; 
30(7):1346-51.
[13] Zhang J, Xie B, Hashimoto K. 
Current status of potential therapeutic 
candidates for the COVID-19 crisis. 
Brain, Behavior, and Immunity. 
2020 Apr 22.
[14] Prasad R. COVID-19: Current 
status, Challenges and Future 
Perspectives. 2020; 1-2.
[15] Kumar BK, Sekhar KV, 
Kunjiappan S, Jamalis J, Balaña-Fouce R, 
Tekwani BL, Sankaranarayanan M. 
Druggable targets of SARS-CoV-2 and 
treatment opportunities for COVID-
19. Bioorganic Chemistry. 2020 Sep 
8:104269.
[16] Baig MS, Alagumuthu M, Rajpoot S, 
Saqib U. Identification of a potential 
peptide inhibitor of SARS-CoV-2 
targeting its entry into the host cells. 
Drugs in R&D. 2020; 20(3):161-9.
[17] Liu T, Luo S, Libby P, Shi GP. 
Cathepsin L-selective inhibitors: 
11
Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.96899
A potentially promising treatment for 
COVID-19 patients. Pharmacology & 
Therapeutics. 2020 May 26:107587.
[18] Iwata-Yoshikawa N, Okamura T, 
Shimizu Y, Hasegawa H, Takeda M, 
Nagata N. TMPRSS2 contributes to 
virus spread and immunopathology 
in the airways of murine models after 
coronavirus infection. Journal of 
Virology. 2019; 93(6).
[19] Belouzard S, Millet JK, Licitra BN, 
Whittaker GR. Mechanisms of 
coronavirus cell entry mediated by 
the viral spike protein. Viruses. 2012; 
4(6):1011-33.
[20] V'kovski P, Gerber M, Kelly J, 
Pfaender S, Ebert N, Lagache SB, 
Simillion C, Portmann J, Stalder H, 
Gaschen V, Bruggmann R. 
Determination of host proteins 
composing the microenvironment 
of coronavirus replicase complexes 
by proximity-labeling. Elife. 2019; 
8:e42037.
[21] V’kovski P, Kratzel A, Steiner S, 
Stalder H, Thiel V. Coronavirus biology 
and replication: implications for SARS-
CoV-2. Nature Reviews Microbiology. 
2020;1-6.
[22] Saxena A. Drug targets for  
COVID-19 therapeutics: Ongoing global 
efforts. Journal of Biosciences. 2020; 
45(1):1-24.
[23] Davidson AM, Wysocki J, Batlle D. 
Interaction of SARS-CoV-2 and other 
Coronavirus with ACE (Angiotensin-
Converting Enzyme)-2 as their main 
receptor: therapeutic implications. 
Hypertension. 2020; 76(5):1339-49.
[24] Fu J, Zhou B, Zhang L, Balaji KS, 
Wei C, Liu X, Chen H, Peng J, Fu J. 
Expressions and significances of the 
angiotensin-converting enzyme 2 gene, 
the receptor of SARS-CoV-2 for COVID-
19. Molecular Biology Reports. 2020; 
47:4383-92.
[25] Wu C, Zheng S, Chen Y, Zheng M. 
Single-cell RNA expression profiling of 
ACE2, the putative receptor of Wuhan 
2019-nCoV, in the nasal tissue. MedRxiv. 
2020 Jan 1.
[26] Tikellis C, Thomas MC. 
Angiotensin-converting enzyme 2 
(ACE2) is a key modulator of the 
renin angiotensin system in health 
and disease. International journal of 
peptides. 2012.
[27] Gómez J, Albaiceta GM, García-
Clemente M, López-Larrea C, 
Amado-Rodríguez L, Lopez-Alonso I, 
Hermida T, Enriquez AI, Herrero P, 
Melón S, Alvarez-Argüelles ME. 
Angiotensin-converting enzymes (ACE, 
ACE2) gene variants and COVID-19 
outcome. Gene. 2020; 762:145102.
[28] Sriram K, Insel PA. A hypothesis 
for pathobiology and treatment of 
COVID-19: The centrality of ACE1/
ACE2 imbalance. British Journal of 
Pharmacology. 2020; 177(21):4825-44.
[29] Rothlin RP, Vetulli HM, Duarte M, 
Pelorosso FG. Telmisartan as tentative 
angiotensin receptor blocker therapeutic 
for COVID-19. Drug Development 
Research. 2020; 81(7): 768-770.
[30] Kuba K, Imai Y, Rao S, Gao H, 
Guo F, Guan B, Huan Y, Yang P, 
Zhang Y, Deng W, Bao L. A crucial role 
of angiotensin converting enzyme 2 
(ACE2) in SARS coronavirus–induced 
lung injury. Nature Medicine. 2005; 
11(8):875-9.
[31] Zhang H, Penninger JM, Li Y, 
Zhong N, Slutsky AS. Angiotensin-
converting enzyme 2 (ACE2) as a 
SARS-CoV-2 receptor: molecular 
mechanisms and potential therapeutic 
target. Intensive Care Medicine. 2020; 
46(4):586-90.
[32] Mukhopadhyay D, Mussa BM. 
Identification of novel hypothalamic 
microRNAs as promising therapeutics 
Biotechnology to Combat COVID-19
12
for SARS-CoV-2 by regulating ACE2 
and TMPRSS2 expression: an in 
silico analysis. Brain Sciences. 2020 
;10(10):666.
[33] Kawase M, Shirato K, van der 
Hoek L, Taguchi F, Matsuyama S. 
Simultaneous treatment of human 
bronchial epithelial cells with serine and 
cysteine protease inhibitors prevents 
severe acute respiratory syndrome 
coronavirus entry. Journal of Virology. 
2012; 86(12):6537-45.
[34] Matsuyama S, Nagata N, Shirato K, 
Kawase M, Takeda M, Taguchi F. 
Efficient activation of the severe acute 
respiratory syndrome coronavirus spike 
protein by the transmembrane protease 
TMPRSS2. Journal of Virology. 2010; 
84(24):12658-64.
[35] Hoffmann M, Kleine-Weber H, 
Schroeder S, Krüger N, Herrler T, 
Erichsen S, Schiergens TS, Herrler G, 
Wu NH, Nitsche A, Müller MA. SARS-
CoV-2 cell entry depends on ACE2 and 
TMPRSS2 and is blocked by a clinically 
proven protease inhibitor. Cell. 2020; 
181(2):271-80.
[36] Shen LW, Mao HJ, Wu YL, 
Tanaka Y, Zhang W. TMPRSS2: A 
potential target for treatment of 
influenza virus and coronavirus 
infections. Biochimie. 2017;142:1-10.
[37] Maggio R, Corsini GU. Repurposing 
the mucolytic cough suppressant and 
TMPRSS2 protease inhibitor bromhexine 
for the prevention and management of 
SARS-CoV-2 infection. Pharmacological 
Research. 2020; 157:104837.
[38] Huang C, Wang Y, Li X, Ren L, 
Zhao J, Hu Y, Zhang L, Fan G, Xu J, 
Gu X, Cheng Z. Clinical features of 
patients infected with 2019 novel 
coronavirus in Wuhan, China. The 
Lancet. 2020; 395(10223):497-506.
[39] Seif F, Aazami H, Khoshmirsafa M, 
Kamali M, Mohsenzadegan M, 
Pornour M, Mansouri D. JAK inhibition 
as a new treatment strategy for patients 
with COVID-19. International Archives 
of Allergy and Immunology. 2020; 
181(6):467-75.
[40] Júnior ML, de Souza LM, Dutra RE, 
de Melo Valente RG, Melo TS. Review 
on therapeutic targets for COVID-
19: insights from cytokine storm. 
Postgraduate Medical Journal. 2020.
[41] Liu CL, Guo J, Zhang X, 
Sukhova GK, Libby P, Shi GP. Cysteine 
protease cathepsins in cardiovascular 
disease: from basic research to clinical 
trials. Nature Reviews Cardiology. 2018; 
15(6):351-70.
[42] Meyer D, Sielaff F, Hammami M, 
Böttcher-Friebertshäuser E, Garten W, 
Steinmetzer T. Identification of the 
first synthetic inhibitors of the type 
II transmembrane serine protease 
TMPRSS2 suitable for inhibition of 
influenza virus activation. Biochemical 
Journal. 2013; 452(2):331-43.
[43] Ou X, Liu Y, Lei X, Li P, Mi D, 
Ren L, Guo L, Guo R, Chen T, Hu J, 
Xiang Z. Characterization of spike 
glycoprotein of SARS-CoV-2 on 
virus entry and its immune cross-
reactivity with SARS-CoV. Nature 
Communications. 2020 Mar 27; 
11(1):1-12.
[44] Hoffmann M, Schroeder S, 
Kleine-Weber H, Müller MA, 
Drosten C, Pöhlmann S. Nafamostat 
mesylate blocks activation of SARS-
CoV-2: new treatment option for 
COVID-19. Antimicrobial Agents and 
Chemotherapy. 2020.
[45] Belen-Apak FB, Sarialioglu F. 
The old but new: Can unfractioned 
heparin and low molecular weight 
heparins inhibit proteolytic activation 
and cellular internalization of SARS-
CoV2 by inhibition of host cell 
proteases. Medical Hypotheses. 2020; 
142:109743.
13
Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.96899
[46] Wu C, Zheng M, Yang Y, Gu X, 
Yang K, Li M, Liu Y, Zhang Q , Zhang P, 
Wang Y, Wang Q . Furin: A Potential 
Therapeutic Target for COVID-19. 
Iscience. 2020; 23(10):101642.
[47] Fitzgerald K. Furin Protease: From 
SARS CoV-2 to Anthrax, Diabetes, and 
Hypertension. The Permanente Journal. 
2020; 24.
[48] Uludağ H, Parent K, Aliabadi HM, 
Haddadi A. Prospects for RNAi 
therapy of COVID-19. Frontiers in 
Bioengineering and Biotechnology. 
2020; 8:916.
[49] Ghosh S, Firdous SM, Nath A. 
siRNA could be a potential therapy 
for COVID-19. EXCLI Journal. 
2020; 19:528.
[50] Huang Y, Yang C, Xu XF, Xu W, 
Liu SW. Structural and functional 
properties of SARS-CoV-2 spike protein: 
potential antivirus drug development 
for COVID-19. Acta Pharmacologica 
Sinica. 2020; 41(9):1141-9.
[51] Xia S, Liu M, Wang C, Xu W, 
Lan Q , Feng S, Qi F, Bao L, Du L, 
Liu S, Qin C. Inhibition of SARS-CoV-2 
(previously 2019-nCoV) infection by a 
highly potent pan-coronavirus fusion 
inhibitor targeting its spike protein 
that harbors a high capacity to mediate 
membrane fusion. Cell Research. 2020; 
30(4):343-55.
[52] Jin Z, Du X, Xu Y, Deng Y, Liu M, 
Zhao Y, Zhang B, Li X, Zhang L, 
Peng C, Duan Y. Structure of M pro 
from SARS-CoV-2 and discovery 
of its inhibitors. Nature. 2020; 
582(7811):289-93.
[53] Macchiagodena M, Pagliai M, 
Procacci P. Identification of potential 
binders of the main protease 3CLpro 
of the COVID-19 via structure-based 
ligand design and molecular modeling. 
Chemical Physics Letters. 2020; 
750:137489.
[54] Bhatnagar T, Murhekar MV, 
Soneja M, Gupta N, Giri S, Wig N, 
Gangakhedkar R. Lopinavir/ritonavir 
combination therapy amongst 
symptomatic coronavirus disease 2019 
patients in India: Protocol for restricted 
public health emergency use. Indian 
Journal of Medical Research. 2020; 
151(2):184.
[55] Wu C, Liu Y, Yang Y, Zhang P, 
Zhong W, Wang Y, Wang Q , Xu Y, Li M, 
Li X, Zheng M. Analysis of therapeutic 
targets for SARS-CoV-2 and discovery 
of potential drugs by computational 
methods. Acta Pharmaceutica Sinica B. 
2020; 10(5):766-88.
[56] Malin JJ, Suárez I, Priesner V, 
Fätkenheuer G, Rybniker J. Remdesivir 
against COVID-19 and other viral 
diseases. Clinical microbiology reviews. 
2020; 34(1).
[57] Monteleone G, Sarzi-Puttini PC, 
Ardizzone S. Preventing COVID-19-
induced pneumonia with anticytokine 
therapy. The Lancet Rheumatology. 
2020; 2(5):e255-6.
[58] Rahmati M, Moosavi MA. Cytokine-
targeted therapy in severely ill COVID-19 
patients: options and cautions. Mortality. 
2020; 105954.
[59] Chi Zhang MD, Zhao Wu PD, 
Jia-Wen Li MD. The cytokine release 
syndrome (CRS) of severe COVID-19 
and Interleukin-6 receptor antagonist 
Tocilizumab may be the key to reduce 
mortality. International Journal 
of Antimicrobial Agents. 2020; 
105954(10.1016).
[60] Duret PM, Sebbag E, Mallick A, 
Gravier S, Spielmann L, Messer L. 
Recovery from COVID-19 in a patient 
with spondyloarthritis treated with TNF-
alpha inhibitor etanercept. Annals of the 
Rheumatic Diseases. 2020; 79(9):1251-2.
[61] Calabrese LH, Calabrese C. 
Cytokine release syndrome and 
Biotechnology to Combat COVID-19
14
the prospects for immunotherapy 
with COVID-19. Part 2: The role of 
interleukin 1. Cleveland Clinic Journal 
of Medicine. 2020 Jul 9. DOI: https://doi.
org/10.3949/ccjm.87a.ccc044.
[62] Cavalli G, De Luca G, 
Campochiaro C, Della-Torre E, Ripa M, 
Canetti D, Oltolini C, Castiglioni B, 
Din CT, Boffini N, Tomelleri A. 
Interleukin-1 blockade with high-dose 
anakinra in patients with COVID-19, 
acute respiratory distress syndrome, 
and hyperinflammation: a retrospective 
cohort study. The Lancet Rheumatology. 
2020; 2(6):e325-31.
[63] Nile SH, Nile A, Qiu J, Li L, Jia X, 
Kai G. COVID-19: Pathogenesis, 
cytokine storm and therapeutic 
potential of interferons. Cytokine & 
Growth Factor Reviews. 2020; 53:66-70.
[64] Eastman RT, Roth JS, 
Brimacombe KR, Simeonov A, Shen M, 
Patnaik S, Hall MD. Remdesivir: a 
review of its discovery and development 
leading to emergency use authorization 
for treatment of COVID-19. ACS 
Central Science. 2020; 6(5):672-83.
[65] McKee DL, Sternberg A, Stange U, 
Laufer S, Naujokat C. Candidate drugs 
against SARS-CoV-2 and COVID-19. 
Pharmacological research. 2020 Apr 
29:104859.
[66] Grein J, Ohmagari N, Shin D, 
Diaz G, Asperges E, Castagna A, 
Feldt T, Green G, Green ML, 
Lescure FX, Nicastri E. Compassionate 
use of remdesivir for patients with 
severe Covid-19. New England Journal 
of Medicine. 2020 ;382(24):2327-36.
[67] Hung IF, Lung KC, Tso EY, Liu R, 
Chung TW, Chu MY, Ng YY, Lo J, 
Chan J, Tam AR, Shum HP. Triple 
combination of interferon beta-1b, 
lopinavir–ritonavir, and ribavirin in 
the treatment of patients admitted to 
hospital with COVID-19: an open-label, 
randomised, phase 2 trial. The Lancet. 
2020; 395(10238):1695-704.
[68] Delang L, Abdelnabi R, 
Neyts J. Favipiravir as a potential 
countermeasure against neglected 
and emerging RNA viruses. Antiviral 
research. 2018; 153:85-94.
[69] Belete TM. An Up-to-Date 
Overview of Therapeutic Agents for 
the Treatment of COVID-19 Disease. 
Clinical pharmacology: advances and 
applications. 2020; 12:203.
[70] Zha L, Li S, Pan L, Tefsen B, 
Li Y, French N, Chen L, Yang G, 
Villanueva EV. Corticosteroid treatment 
of patients with coronavirus disease 
2019 (COVID-19). Medical Journal of 
Australia. 2020; 212(9):416-20.
[71] van Paassen J, Vos JS, Hoekstra EM, 
Neumann KM, Boot PC, Arbous SM. 
Corticosteroid use in COVID-19 
patients: a systematic review and meta-
analysis on clinical outcomes. Critical 
Care. 2020; 24(1):1-22.
[72] Wu C, Chen X, Cai Y, Zhou X, Xu S, 
Huang H, Zhang L, Zhou X, Du C, 
Zhang Y, Song J. Risk factors associated 
with acute respiratory distress 
syndrome and death in patients with 
coronavirus disease 2019 pneumonia 
in Wuhan, China. JAMA Internal 
Medicine. 2020; 180(7):934-43.
[73] Mishra GP, Mulani J. Corticosteroids 
for COVID-19: the search for an 
optimum duration of therapy. The 
Lancet. Respiratory Medicine. 2021; 
9(1):e8.
[74] Wang X, Guo X, Xin Q , Pan Y, 
Hu Y, Li J, Chu Y, Feng Y, Wang Q . 
Neutralizing antibodies responses to 
SARS-CoV-2 in COVID-19 inpatients 
and convalescent patients. Clinical 
Infectious Diseases. 2020.
[75] Bloch EM, Shoham S, Casadevall A, 
Sachais BS, Shaz B, Winters JL, Van 
Buskirk C, Grossman BJ, Joyner M, 
Henderson JP, Pekosz A. Deployment 
of convalescent plasma for the 
prevention and treatment of COVID-19. 
15
Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.96899
The Journal of clinical investigation. 
2020; 130(6):2757-65.
[76] Duan K, Liu B, Li C, Zhang H, 
Yu T, Qu J, Zhou M, Chen L, Meng S, 
Hu Y, Peng C. Effectiveness of 
convalescent plasma therapy in severe 
COVID-19 patients. Proceedings of 
the National Academy of Sciences. 
2020;117(17):9490-6.
[77] Salazar E, Perez KK, Ashraf M, 
Chen J, Castillo B, Christensen PA, 
Eubank T, Bernard DW, Eagar TN, 
Long SW, Subedi S. Treatment of 
coronavirus disease 2019 (COVID-19) 
patients with convalescent plasma. The 
American Journal of Pathology. 2020; 
190(8):1680-90.
[78] Trivedi N, Verma A, Kumar D. 
Possible treatment and strategies for 
COVID-19: review and assessment. 
European Review for Medical and 
Pharmacological Sciences. 2020; 
24(23):12593-608.
[79] Padhy BM, Mohanty RR, Das S, 
Meher BR. Therapeutic potential of 
ivermectin as add on treatment in 
COVID 19: A systematic review and 
meta-analysis: Ivermectin in COVID-19: 
A meta-analysis. Journal of Pharmacy 
& Pharmaceutical Sciences. 2020; 
23:462-9.
[80] Caly L, Druce JD, Catton MG, 
Jans DA, Wagstaff KM. The FDA-
approved drug ivermectin inhibits the 
replication of SARS-CoV-2 in vitro. 
Antiviral Research. 2020; 178:104787.
[81] Choudhary R, Sharma AK. Potential 
use of hydroxychloroquine, ivermectin 
and azithromycin drugs in fighting 
COVID-19: trends, scope and relevance. 
New Microbes and New Infections. 
2020:100684.
[82] dos Reis Neto ET, Kakehasi AM, 
de Medeiros Pinheiro M, Ferreira GA, 
Marques CD, da Mota LM, dos 
Santos Paiva E, Pileggi GC, Sato EI, 
Reis AP, Xavier RM. Revisiting 
hydroxychloroquine and chloroquine 
for patients with chronic immunity-
mediated inflammatory rheumatic 
diseases. Advances in Rheumatology. 
2020; 60(1):1-1.
[83] Jorge A. Hydroxychloroquine in the 
prevention of COVID-19 mortality. The 
Lancet Rheumatology. 2021; 3(1):e2-3.
[84] Juurlink DN. Safety considerations 
with chloroquine, hydroxychloroquine 
and azithromycin in the management 
of SARS-CoV-2 infection. Canadian 
Medical Association Journal. 2020; 
192(17):E450-3.
[85] Wang M, Cao R, Zhang L, Yang X, 
Liu J, Xu M, Shi Z, Hu Z, Zhong W, 
Xiao G. Remdesivir and chloroquine 
effectively inhibit the recently emerged 
novel coronavirus (2019-nCoV) in vitro. 
Cell Research. 2020; 30(3):269-71.
[86] Yao X, Ye F, Zhang M, Cui C, 
Huang B, Niu P, Liu X, Zhao L, Dong E, 
Song C, Zhan S. In vitro antiviral activity 
and projection of optimized dosing design 
of hydroxychloroquine for the treatment 
of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Clinical 
Infectious Diseases. 2020; 71(15):732-9.
[87] Rentsch CT, DeVito NJ, 
MacKenna B, Morton CE, Bhaskaran K, 
Brown JP, Goldacre B. Effect of pre-
exposure use of hydroxychloroquine 
on COVID-19 mortality: a population-
based cohort study in patients with 
rheumatoid arthritis or systemic lupus 
erythematosus using the Open SAFELY 
platform. The Lancet Rheumatology, 
2021; 3(1): e19-e27.
[88] Geleris J, Sun Y, Platt J, Zucker J, 
Baldwin M, Hripcsak G, Labella A, 
Manson DK, Kubin C, Barr RG, 
Sobieszczyk ME. Observational 
study of hydroxychloroquine in 
hospitalized patients with Covid-19. 
New England Journal of Medicine. 2020; 
382(25):2411-8.
Biotechnology to Combat COVID-19
16
[89] Yadav T, Srivastava N, Mishra G, 
Dhama K, Kumar S, Puri B, Saxena SK. 
Recombinant vaccines for COVID-19. 
Human Vaccines & Immunotherapeutics. 
2020; 16(12):2905-12.
[90] Krammer F. SARS-CoV-2 vaccines 
in development. Nature. 2020; 
586(7830):516-27.
[91] Gao Q , Bao L, Mao H, Wang L, 
Xu K, Yang M, Li Y, Zhu L, Wang N, 
Lv Z, Gao H. Development of an 
inactivated vaccine candidate for SARS-
CoV-2. Science. 2020; 369(6499):77-81.
[92] Tumban E. Lead SARS-CoV-2 
Candidate Vaccines: Expectations from 
Phase III Trials and Recommendations 
Post-Vaccine Approval. Viruses. 
2021;13(1):54
[93] Tregoning JS, Brown ES, 
Cheeseman HM, Flight KE, Higham SL, 
Lemm NM, Pierce BF, Stirling DC, 
Wang Z, Pollock KM. Vaccines for 
COVID-19. Clinical & Experimental 
Immunology. 2020; 202(2):162-92.
[94] COVAXIN® -India's first indigenous 
COVID-19 vaccine. Bharat Biotech. 
(http://www.bharatbiotech.com).
[95] Batty CJ, Heise MT, Bachelder EM, 
Ainslie KM. Vaccine formulations in 
clinical development for the prevention 
of severe acute respiratory syndrome 
coronavirus 2 infection. Advanced Drug 
Delivery Reviews. 2020 Dec 13.
[96] Inovio expects to begin late-stage 
COVID-19 vaccine study in second 
quarter. Thomson Reuters Foundation 
news, 10 Feb, 2021.
[97] Buschmann MD, Carrasco MJ, 
Alishetty S, Paige M, Alameh MG, 
Weissman D. Nanomaterial Delivery 
Systems for mRNA Vaccines. Vaccines. 
2021; 9(1):65.
[98] Moderna announces primary 
efficacy analysis in phase 3 COVE study 
for its COVID-19 vaccine candidate 
and filing today with U.S. FDA for 
emergency use authorization. Moderna 
Press Release. November 30, 2020.
[99] Oliver SE, Gargano JW, 
Marin M, Wallace M, Curran KG, 
Chamberland M, McClung N, Campos-
Outcalt D, Morgan RL, Mbaeyi S, 
Romero JR. The Advisory Committee 
on Immunization Practices’ Interim 
Recommendation for Use of Pfizer-
BioNTech COVID-19 Vaccine—United 
States, December 2020. Morbidity 
and Mortality Weekly Report. 2020 ; 
69(50):1922.
[100] Dai L, Gao GF. Viral targets for 
vaccines against COVID-19. Nature 
Reviews Immunology. 2020;1-10.
[101] Novavax to seek EUA for 
covid-19 vaccine as early as april. 
Medscape Medical News, 26 Feb, 
2021. (https://www.medscape.com/
viewarticle/946422).
[102] Ng WH, Liu X, Mahalingam S. 
Development of vaccines for SARS-
CoV-2. F1000Research. 2020; 9.
[103] WHO gives emergency use 
approval to AstraZeneca-Oxford's 






[104] Nikhra V. Stages in COVID-19 
Vaccine Development: The Nemesis, 
the Hubris, and the Elpis. International 
Journal Clinical Virology. 2020; 
4:126-35.
